Fibronectin fibrils regulate TGF-β1-induced Epithelial-Mesenchymal Transition

Matrix Biology

Volumn 60-61, Issue , 2017, Pages 157-175

  Griggs, Lauren A ^a   Hassan, Nadiah T ^a   Malik, Roshni S ^a   Griffin, Brian P ^a   Martinez, Brittany A ^a   Elmore, Lynne W ^b,c   Lemmon, Christopher A ^a,c  

^a Virginia Commonwealth University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Epithelial Mesenchymal Transition; Extracellular matrix; Fibronectin; TGF 1

Indexed keywords

COMPLEMENTARY DNA; FIBRONECTIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; BACTERIAL PROTEIN; CYTOKINE; MIGRATION STIMULATING FACTOR, HUMAN; MONOCLONAL ANTIBODY; PROTEIN BINDING; SMAD2 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN;

ARTICLE; BREAST EPITHELIUM CELL; CELL DENSITY; CELL MIGRATION; CELL TRANSDIFFERENTIATION; COMPARATIVE STUDY; CONDITIONED MEDIUM; DELETION MUTANT; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LONG TERM EXPOSURE; MDCK-II CELL LINE; MECHANOTRANSDUCTION; PHENOTYPE; PRIORITY JOURNAL; STRESS FIBER; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOMECHANICS; BIOSYNTHESIS; CELL MOTION; CHEMISTRY; CYTOLOGY; DOG; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; MDCK CELL LINE; METABOLISM; MUTATION; SIGNAL TRANSDUCTION; STREPTOCOCCUS PYOGENES; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; BIOMECHANICAL PHENOMENA; CELL LINE, TUMOR; CELL MOVEMENT; CYTOKINES; DOGS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; STREPTOCOCCUS PYOGENES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85010866392     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2017.01.001     Document Type: Article

References (92)

1. Thiery, J.P., Sleeman, J.P., Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7:2 (2006), 131–142.
2. Hay, E.D., The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev. Dyn. 233:3 (2005), 706–720.
3. Yan, C., Grimm, W.A., Garner, W.L., Qin, L., Travis, T., Tan, N., Han, Y.P., Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor-alpha through bone morphogenic protein-2. Am. J. Pathol. 176:5 (2010), 2247–2258.
4. Shook, D., Keller, R., Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech. Dev. 120:11 (2003), 1351–1383.
5. Nieto, M.A., The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 27 (2011), 347–376.
6. Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139:5 (2009), 871–890.
7. Hay, E.D., An overview of epithelio-mesenchymal transformation. Acta Anat. 154:1 (1995), 8–20.
8. Bhowmick, N.A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C.A., Engel, M.E., Arteaga, C.L., Moses, H.L., Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12:1 (2001), 27–36.
9. Xu, J., Lamouille, S., Derynck, R., TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19:2 (2009), 156–172.
10. Gupta, P.B., Chaffer, C.L., Weinberg, R.A., Cancer stem cells: mirage or reality?. Nat. Med. 15:9 (2009), 1010–1012.
11. Massagué, J., TGFbeta in cancer. Cell 134:2 (2008), 215–230.
12. Thiery, J.P., Epithelial–mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15:6 (2003), 740–746.
13. Derynck, R., Akhurst, R.J., Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat. Cell Biol. 9:9 (2007), 1000–1004.
14. Mats, G., Åsa, F., Jan-Olof, K., Lars, E.E., Nils-Erik, H., Mikael, N., Transforming growth factor-β and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J. Cell Sci. 115:22 (2002), 4227–4236.
15. Hui-Wen, L., Sheng-Chieh, H., Weiya, X., Xinyu, C., Jin-Yuan, S., Yongkun, W., James, L.A., Gabriel, N.H., Mien-Chie, H., Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 67:19 (2007), 9066–9076.
16. Aristidis, M., Carl-Henrik, H., Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci., 98(10), 2007.
17. O'Connor, J.W., Gomez, E.W., Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clin. Transl. Med., 3, 2013, 23.
18. O'Connor, J.W., Riley, P.N., Nalluri, S.M., Ashar, P.K., Gomez, E.W., Matrix rigidity mediates TGFbeta1-induced epithelial-myofibroblast transition by controlling cytoskeletal organization and MRTF-A localization. J. Cell. Physiol. 230:8 (2015), 1829–1839.
19. McGrail, D.J., Kieu, Q.M., Dawson, M.R., The malignancy of metastatic ovarian cancer cells is increased on soft matrices through a mechanosensitive Rho-ROCK pathway. J. Cell Sci. 127:Pt 12 (2014), 2621–2626.
20. Lee, K., Chen, Q.K., Lui, C., Cichon, M.A., Radisky, D.C., Nelson, C.M., Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol. Biol. Cell 23:20 (2012), 4097–4108.
21. Markowski, M.C., Brown, A.C., Barker, T.H., Directing epithelial to mesenchymal transition through engineered microenvironments displaying orthogonal adhesive and mechanical cues. J. Biomed. Mater. Res. A 100:8 (2012), 2119–2127.
22. Brown, A.C., Fiore, V.F., Sulchek, T.A., Barker, T.H., Physical and chemical microenvironmental cues orthogonally control the degree and duration of fibrosis-associated epithelial-to-mesenchymal transitions. J. Pathol. 229:1 (2013), 25–35.
23. Leight, J.L., Wozniak, M.A., Chen, S., Lynch, M.L., Chen, C.S., Matrix rigidity regulates a switch between TGF-beta1-induced apoptosis and epithelial-mesenchymal transition. Mol. Biol. Cell 23:5 (2012), 781–791.
24. Spencer, C.W., Laurent, F., Jeff, H.T., Yurong, G., Vincent, H.P., Hannah, E.M., Albert, C.C., Robert, L.S., Susan, S.T., Adam, J.E., Jing, Y., Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat. Cell Biol., 17(5), 2015.
25. Hinz, B., Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr. Rheumatol. Rep. 11:2 (2009), 120–126.
26. Gomez, E.W., Chen, Q.K., Gjorevski, N., Nelson, C.M., Tissue geometry patterns epithelial-mesenchymal transition via intercellular mechanotransduction. J. Cell. Biochem. 110:1 (2010), 44–51.
27. Giacomini, M., Travis, M., Kudo, M., Sheppard, D., Epithelial cells utilize cortical actin/myosin to activate latent TGF-β through integrin α(v)β(6)-dependent physical force. Exp. Cell Res. 318:6 (2012), 716–722.
28. Masszi, A., Di Ciano, C., Sirokmány, G., Arthur, W.T., Rotstein, O.D., Wang, J., McCulloch, C.A., Rosivall, L., Mucsi, I., Kapus, A., Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am. J. Physiol. Ren. Physiol., 284(5), 2003, 24.
29. Gjorevski, N., Boghaert, E., Nelson, C.M., Regulation of epithelial-mesenchymal transition by transmission of mechanical stress through epithelial tissues. Cancer Microenviron. 5:1 (2012), 29–38.
30. Hynes, R.O., The extracellular matrix: not just pretty fibrils. Science 326:5957 (2009), 1216–1219.
31. Chen, C.S., Tan, J., Tien, J., Mechanotransduction at cell-matrix and cell-cell contacts. Annu. Rev. Biomed. Eng. 6 (2004), 275–302.
32. Butcher, D.T., Alliston, T., Weaver, V.M., A tense situation: forcing tumour progression. Nat. Rev. Cancer 9:2 (2009), 108–122.
33. Geiger, B., Bershadsky, A., Pankov, R., Yamada, K.M., Transmembrane crosstalk between the extracellular matrix–cytoskeleton crosstalk. Nat. Rev. Mol. Cell Biol. 2:11 (2001), 793–805.
34. Pankov, R., Fibronectin at a glance. J. Cell Sci. 115:20 (2002), 3861–3863.
35. Jill, C.S., Elof, E., Steven, P.S., Noelynn, O., Fibronectin gene expression differs in normal and abnormal human wound healing. Wound Repair Regen., 2(1), 1994.
36. Clark, R.A., Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. J. Investig. Dermatol., 94(Suppl. 6), 1990.
37. George, E.L., Georges-Labouesse, E.N., Patel-King, R.S., Rayburn, H., Hynes, R.O., Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119:4 (1993), 1079–1091.
38. Takayoshi, S., Melinda, L., Kenneth, M.Y., Fibronectin requirement in branching morphogenesis. Nature 423:6942 (2003), 876–881.
39. Bae, Y.K., Kim, A., Kim, M.K., Choi, J.E., Kang, S.H., Lee, S.J., Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum. Pathol., 2013.
40. Castellani, P., Siri, A., Rosellini, C., Infusini, E., Borsi, L., Zardi, L., Transformed human cells release different fibronectin variants than do normal cells. J. Cell Biol. 103:5 (1986), 1671–1677.
41. Svante, S., Antti, V., Fibronectin in human solid tumors. Int. J. Cancer 27:4 (1981), 427–435.
42. Kadar, A., Tõkés, A.-M.M., Kulka, J., Robert, L., Extracellular matrix components in breast carcinomas. Semin. Cancer Biol. 12:3 (2002), 243–257.
43. Halliday, N.L., Tomasek, J.J., Mechanical properties of the extracellular matrix influence fibronectin fibril assembly in vitro. Exp. Cell Res. 217:1 (1995), 109–117.
44. Baneyx, G., Baugh, L., Vogel, V., Fibronectin extension and unfolding within cell matrix fibrils controlled by cytoskeletal tension. Proc. Natl. Acad. Sci. U. S. A. 99:8 (2002), 5139–5143.
45. Martino, M.M., Hubbell, J.A., The 12th–14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J. 24:12 (2010), 4711–4721.
46. Dallas, S.L., Keene, D.R., Bruder, S.P., Saharinen, J., Sakai, L.Y., Mundy, G.R., Bonewald, L.F., Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 15:1 (2000), 68–81.
47. Dallas, S.L., Sivakumar, P., Jones, C.J., Chen, Q., Peters, D.M., Mosher, D.F., Humphries, M.J., Kielty, C.M., Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J. Biol. Chem. 280:19 (2005), 18871–18880.
48. Chen, Q., Sivakumar, P., Barley, C., Peters, D.M., Gomes, R.R., Farach-Carson, M.C., Dallas, S.L., Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein-1. J. Biol. Chem. 282:36 (2007), 26418–26430.
49. Taipale, J., Miyazono, K., Heldin, C.H., Keski-Oja, J., Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell Biol. 124:1–2 (1994), 171–181.
50. Jeng, M.H., ten Dijke, P., Iwata, K.K., Jordan, V.C., Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol. Cell. Endocrinol. 97:1–2 (1993), 115–123.
51. Arrick, B.A., Korc, M., Derynck, R., Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res. 50:2 (1990), 299–303.
52. Martinez-Carpio, P.A., Mur, C., Fernandez-Montoli, M.E., Ramon, J.M., Rosel, P., Navarro, M.A., Secretion and dual regulation between epidermal growth factor and transforming growth factor-beta1 in MDA-MB-231 cell line in 42-hour-long cultures. Cancer Lett. 147:1–2 (1999), 25–29.
53. Wikner, N.E., Persichitte, K.A., Baskin, J.B., Nielsen, L.D., Clark, R.A., Transforming growth factor-beta stimulates the expression of fibronectin by human keratinocytes. J. Investig. Dermatol. 91:3 (1988), 207–212.
54. Ignotz, R.A., Endo, T., Massague, J., Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J. Biol. Chem. 262:14 (1987), 6443–6446.
55. Roberts, C.J., Birkenmeier, T.M., McQuillan, J.J., Akiyama, S.K., Yamada, S.S., Chen, W.T., Yamada, K.M., McDonald, J.A., Transforming growth factor beta stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts. J. Biol. Chem. 263:10 (1988), 4586–4592.
56. Ignotz, R.A., Massague, J., Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 261:9 (1986), 4337–4345.
57. Tomasini-Johansson, B.R., Kaufman, N.R., Ensenberger, M.G., Ozeri, V., Hanski, E., Mosher, D.F., A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly. J. Biol. Chem. 276:26 (2001), 23430–23439.
58. Altrock, E., Sens, C., Wuerfel, C., Vasel, M., Kawelke, N., Dooley, S., Sottile, J., Nakchbandi, I.A., Inhibition of fibronectin deposition improves experimental liver fibrosis. J. Hepatol. 62:3 (2015), 625–633.
59. Christine, G., Erik, W.T., The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J., 2(1), 1996.
60. Kang, Y., Massague, J., Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:3 (2004), 277–279.
61. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., Savagner, P., Gitelman, I., Richardson, A., Weinberg, R.A., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:7 (2004), 927–939.
62. Massague, J., How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 1:3 (2000), 169–178.
63. Derynck, R., Feng, X.H., TGF-beta receptor signaling. Biochim. Biophys. Acta 1333:2 (1997), F105–F150.
64. Lamouille, S., Derynck, R., Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J. Cell Biol. 178:3 (2007), 437–451.
65. Barnard, J.A., Bascom, C.C., Lyons, R.M., Sipes, N.J., Moses, H.L., Transforming growth factor beta in the control of epidermal proliferation. Am. J. Med. Sci. 296:3 (1988), 159–163.
66. Moses, H., Barcellos-Hoff, M.H., TGF-beta biology in mammary development and breast cancer. Cold Spring Harb. Perspect. Biol., 3(1), 2011, a003277.
67. Kalluri, R., Weinberg, R.A., The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119:6 (2009), 1420–1428.
68. Peters, D.M., Portz, L.M., Fullenwider, J., Mosher, D.F., Co-assembly of plasma and cellular fibronectins into fibrils in human fibroblast cultures. J. Cell Biol. 111:1 (1990), 249–256.
69. Haglund, C., Ylatupa, S., Mertaniemi, P., Partanen, P., Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br. J. Cancer 76:6 (1997), 777–783.
70. Ylatupa, S., Haglund, C., Mertaniemi, P., Vahtera, E., Partanen, P., Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br. J. Cancer 71:3 (1995), 578–582.
71. Choate, J.J., Mosher, D.F., Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia. Cancer 51:6 (1983), 1142–1147.
72. Das, T., Safferling, K., Rausch, S., Grabe, N., Boehm, H., Spatz, J.P., A molecular mechanotransduction pathway regulates collective migration of epithelial cells. Nat. Cell Biol. 17:3 (2015), 276–287.
73. Wozniak, M.A., Desai, R., Solski, P.A., Der, C.J., Keely, P.J., ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J. Cell Biol. 163:3 (2003), 583–595.
74. Poincloux, R., Collin, O., Lizarraga, F., Romao, M., Debray, M., Piel, M., Chavrier, P., Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc. Natl. Acad. Sci. U. S. A. 108:5 (2011), 1943–1948.
75. Ishihara, H., Martin, B.L., Brautigan, D.L., Karaki, H., Ozaki, H., Kato, Y., Fusetani, N., Watabe, S., Hashimoto, K., Uemura, D., et al. Calyculin a and okadaic acid: inhibitors of protein phosphatase activity. Biochem. Biophys. Res. Commun. 159:3 (1989), 871–877.
76. Kamaraju, A.K., Roberts, A.B., Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280:2 (2005), 1024–1036.
77. Fleming, Y.M., Ferguson, G.J., Spender, L.C., Larsson, J., Karlsson, S., Ozanne, B.W., Grosse, R., Inman, G.J., TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation. Oncogene 28:7 (2009), 983–993.
78. Zhong, C.L., Chrzanowska-Wodnicka, M., Brown, J., Shaub, A., Belkin, A.M., Burridge, K., Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J. Cell Biol. 141:2 (1998), 539–551.
79. Hubbard, B., Buczek-Thomas, J.A., Nugent, M.A., Smith, M.L., Heparin-dependent regulation of fibronectin matrix conformation. Matrix Biol. 34 (2014), 124–131.
80. Zhu, J., Clark, R.A., Fibronectin at select sites binds multiple growth factors and enhances their activity: expansion of the collaborative ECM-GF paradigm. J. Investig. Dermatol. 134:4 (2014), 895–901.
81. Johnson, K.J., Sage, H., Briscoe, G., Erickson, H.P., The compact conformation of fibronectin is determined by intramolecular ionic interactions. J. Biol. Chem. 274:22 (1999), 15473–15479.
82. Scott, L.E., Mair, D.B., Narang, J.D., Feleke, K., Lemmon, C.A., Fibronectin fibrillogenesis facilitates mechano-dependent cell spreading, force generation, and nuclear size in human embryonic fibroblasts. Integr. Biol. 7:11 (2015), 1454–1465.
83. Tan, W.H., Popel, A.S., Mac Gabhann, F., Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking. Cell. Signal. 25:12 (2013), 2496–2510.
84. Kim, K.K., Kugler, M.C., Wolters, P.J., Robillard, L., Galvez, M.G., Brumwell, A.N., Sheppard, D., Chapman, H.A., Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 103:35 (2006), 13180–13185.
85. Park, J., Schwarzbauer, J.E., Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene, 2013.
86. Marcello, G., Barbara, R., Gianmario, B., The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:3 (2007), 305–318.
87. Thompson, E.W., Newgreen, D.F., Tarin, D., Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res. 65:14 (2005), 5991–5995 (discussion 5995).
88. Wells, R.G., The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow?. Hepatology 51:3 (2010), 737–740.
89. Youhua, L., Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15:1 (2004), 1–12.
90. Lemmon, C.A., Ohashi, T., Erickson, H.P., Probing the folded state of fibronectin type III domains in stretched fibrils by measuring buried cysteine accessibility. J. Biol. Chem. 286:30 (2011), 26375–26382.
91. Beacham, D.A., Amatangelo, M.D., Cukierman, E., Preparation of extracellular matrices produced by cultured and primary fibroblasts. Curr. Protoc. Cell Biol., 2007 (Chapter 10 Unit 10 9).
92. Beisker, W., Dolbeare, F., Gray, J.W., An improved immunocytochemical procedure for high-sensitivity detection of incorporated bromodeoxyuridine. Cytometry 8:2 (1987), 235–239.